Influence of iron status in the response to the deferoxamine test

Journal of the American Society of Nephrology

Volumn 7, Issue 1, 1996, Pages 135-139

  Cannata, Jorge B ^a,c   Fernández Martín, José L ^a   Díaz López, Bernardino ^a   Alonso, Mario ^a   Olaizola, Inés ^a   Acuña, Gonzálo ^a   Caramelo, Carlos ^b   Alvarez Grande, Jaime ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Renal Unit   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Aluminum; Chelating agents; Iron; Transferrin

Indexed keywords

ALUMINUM; DEFEROXAMINE; IRON; TRANSFERRIN;

ARTICLE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC TEST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON METABOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030027064     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v71135     Document Type: Article

References (24)

1. Trapp GA: Plasma aluminum is bound to transferrin. Life Sci 1983;33:311-315.
2. Ackrill P, Day P: The use of desferrioximine in dialysis-associated aluminium disease. Contrib Nephrol 1993; 102:125-134.
3. Konthoghiorghes GJ, Barr J, Baillod RA: Aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Drugs Today 1992;28:183-187.
4. Elorriaga R, Fernández Martín JL, Menéndez Fraga P, Naves ML, Braga S, Cannata JB: Aluminium removal: Short and long term preliminary results with L1 in rats. Drugs Today 1992;28:177-182.
5. Cannata JB, Díaz López JB: Insights into the complex aluminium and iron relationship. Nephrol Dial Transplant 1991;6:605-607.
6. Caramelo CA, Cannata JB, Rodeles MR, et al.: Mechanisms of aluminum-induced microcytosis: Lessons from a case of aluminum intoxication. Kidney Int 1995;47: 164-168.
7. Cannata JB, Olaizola IR, Gómez Alonso C, Menéndez Fraga P, Alonso Suarez M, Díaz López J: Serum aluminum transport and aluminum uptake in chronic renal failure: Role of iron and aluminum metabolism. Nephron 1993;65:141-146.
8. Yi Huang J, Huang CC, Lim PS, Wu MS, Leu ML: Effect of body iron stores on serum aluminum level in hemodialysis patients. Nephron 1992;62:158-162.
9. Vanuytsel JL, D'Haese PC, Couttenye MM, De Broe ME: Higher serum aluminium concentrations in iron-depleted dialysis patients [Letter]. Nephrol Dial Transplant 1992;7:117.
10. Consensus Conference: Diagnosis and treatment of aluminium overload in end-stage renal failure. Nephrol Dial Transplant 1993;8:1-4.
11. Milliner DS, Nebeker HG, Ott SM, et al.: Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 1984;101: 775-780.
12. Sanz-Medel A, Rodríguez-Roza R, González Alonso R, Noval Vallina A: Atomic spectrometric methods (atomic absorption and atomic emission) for the determination of aluminium at the parts per billion level in biological fluids. J Anal Atom Spectr 1987;2:177-184.
13. Fernández-Martín JL, Menéndez Fraga P, Canteros A, Díaz López JB, Cannata JB: Binding of aluminium to plasma proteins: Comparative effect of desferrioxamine and deferiprone (L1). Clin Chim Acta 1994;230:137-145.
14. Cannata JB, Fernández-Soto I, Fernández-Menéndez MJ, et al.: Role of iron metabolism in absorption and cellular uptake of aluminium. Kidney Int 1991;39:799-803.
15. D'Haese PC, Clement JP, Elseviers MM, et al.: Value of serum aluminium monitoring in dialysis patients: A multicentre study. Nephrol Dial Transplant 1990;5:45-53.
16. Martin RB, Savory J, Brown S, Bertholf RL, Wills MR: Transferrin binding of Al3+ and Fe3+. Clin Chem. 1987; 33:405-407.
17. Drücke TB: Adynamic bone disease, anaemia, resistance to erythropoietin and iron-aluminium interaction. Nephrol Dial Transplant 1993;8:12-16.
18. Abreo K, Glass J: Cellular, biochemical, and molecular mechanism of aluminium toxicity. Nephrol Dial Transplant 1993;8:5-11.
19. D'Haese PC, Lemoniatou E, Lamberts LV, Vanuytsel, Couttenye MM, De Broe ME: Effect of iron (Fe)-status on the accumulation/distribution of aluminum. Kidney Int 1992;41:1433.
20. Nebeker HG, Andress DL, Milliner DS, et al.: Indirect methods for the diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Kidney Int 1986;18[Suppl]:S96-S99.
21. Cannata JB: Utilidad de la desferrioxamina en el diagnóstico y tratamiento de la intoxicación alumínica. Nefrología 1992;12:295-301.
22. Pey Y, Hercz G, Greenwood C, et al.: Non invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int 1992;41:1374-1382.
23. Hümpfner A, Hummel S, Schulz W: Diagnostic and therapeutic approaches to aluminium overload in dialysis patients: Representative study by questionnaire in West German dialysis units in 1990-1989. Nephrol Dial Transplant 1993;8[Suppl 1]:51-54.
24. Grosso S, Barreto S, Canteros A, et al.: Prevention, diagnosis and treatment of aluminium toxicity in Spain: A multicenter questionnairy (Abstract). Nephrol Dial Transplant 1995, in press.